)
Edge
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
SanBio Company
SanBio Company (4592) investor relations material
SanBio Company Q1 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2027 earnings summary15 Jun, 2026
Executive summary
Advanced regulatory progress for regenerative medicine in Japan and the U.S., with AKUUGO® receiving NHI price listing and commercial launch in Japan in May 2026.
Continued R&D focus on SB623 for central nervous system diseases, with Phase 3 trial preparations in the U.S. and ischemic stroke program discussions in Japan.
Operating loss narrowed to ¥953 million from ¥1,007 million year-over-year; net loss attributable to owners of parent improved to ¥836 million from ¥1,531 million.
Financial highlights
Operating revenue for the quarter was ¥680 million, with R&D expenses at ¥680 million.
Operating loss was ¥953 million, ordinary loss ¥779 million, and net loss attributable to owners of parent ¥836 million, all improved from the prior year.
Foreign exchange gains of ¥177 million recorded as non-operating income.
Comprehensive income was negative ¥972 million, compared to negative ¥880 million year-over-year.
Outlook and guidance
No revisions to the previously announced financial results forecast for the first half and full year.
Full-year forecast projects operating loss of ¥5,229 million and net loss per share of ¥65.77.
Revenue outlook following AKUUGO NHI listing
Capital requirements for U.S. Phase 3 initiation
PMDA discussion goals for ischemic stroke trial
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from SanBio Company
- AKUUGO® approved in Japan, fueling R&D and expansion, but losses expected to deepen.4592
Q4 202625 Mar 2026 - Net loss widened to ¥2,713 million; major funding secured for AKUUGO® and clinical trials.4592Q3 202615 Dec 2025
- Akugo/AKUUGO® gains conditional approval in Japan as losses narrow and global expansion advances.4592Q2 20253 Oct 2025
- Losses widened on higher R&D and FX losses; financing secured, AKUUGO® approval expected.4592Q2 20263 Oct 2025
- AKUUGO® approved in Japan; global expansion and clinical trials continue amid high R&D costs.4592Q4 20253 Oct 2025
- Net loss improved, regulatory decision on SB623 expected in June, no dividend planned.4592Q1 20253 Oct 2025
- AKUUGO® approved in Japan; shipment delayed, ¥1.9B raised for launch and promotion.4592Q3 20253 Oct 2025
- Q1 net loss deepened to ¥1,531 million as AKUUGO® nears launch and new funding is secured.4592Q1 20263 Oct 2025
Next SanBio Company earnings date
Q2 202711 Sep, 2026
SanBio Company
Next SanBio Company earnings date
Q2 202711 Sep, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Explore our global coverage